Johnson & Johnson Reports meta-analysis Data for Copanlisib in Neuromyelitis optica spectrum disorder

Johnson & Johnson today announced meta-analysis results for Copanlisib in patients with Neuromyelitis optica spectrum disorder. The study demonstrated that Copanlisib demonstrates favorable safety profile compared to standard of care or placebo. These results provide important insights into the treatment of Neuromyelitis optica spectrum disorder and support the continued development of Copanlisib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Copanlisib was consistent with previous observations, with no new safety signals identified.